EFPIA：2025年在较小的欧盟市场，创新药物不可用和延迟的根源：缩短患者获得创新药物的时间报告（英文版）

EFPIA has looked for many years at the length of time it takes for medicines to be made available. As illustrated by the most recent data in the Patient W.A.I.T. Indicator Survey in 2023, the average time to reimbursement for innovative treatments across the European Union (EU) and European Economic Area (EEA) countries has reached 578 days.2 There are significant differences in the time taken prior to national reimbursement. The industry shares concerns about these delays and recognises that